Synexa Insights
The Latest Insights From Our Scientists
From Signals to Systems: Olink Proteomics as a Cornerstone of Synexa’s Biomarker Strategy
We have entered a new era of modern science, where therapeutic innovation is reshaping the field of medicine.…
GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions
Good Manufacturing Practice ligand binding and potency assays are essential for ensuring the quality, safety, and regulatory compliance of biopharmaceutical…
Validating Immunity: How ELISpot Data Shaped the AELIX-003 HIV Cure Trial
We are proud to share our laboratory’s role in a landmark clinical study published in Nature Communications, titled “Safety, immunogenicity…
From Pathways to Proof: Targeted Phosphoproteomics and PTM Analysis with LC-MS/MS
Quadrupole mass spectrometry (LC-MS/MS) has long established itself as the workhorse of bioanalysis for small molecules, valued for its high…
Establishing Biosimilarity: Regulatory and Scientific Expectations
A biosimilar is defined as a biologic product, highly similar to a reference or originator, with no clinically meaningful differences…
Why The Future Of Precision Medicine Will Be Defined By The Quality And Strategy Of Biomarker Signatures
We’re in the midst of a paradigm shift in biomarker science. No longer academic luxuries or exploratory afterthoughts, biomarker signatures…
Radiopharmaceutical Drug Development: A Bioanalytical Lab Perspective
The radiopharmaceutical industry has traditionally experienced steady but modest growth, primarily driven by its established role in diagnostics and nuclear…
Building a bioanalytical workflow for a vaccine study: The key assays and considerations
The COVID-19 pandemic put vaccines under the spotlight again, and from a scientific perspective at least, innovations have abounded.…
Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach
Oligonucleotide therapeutics have revolutionised the field of medicine over the last decade due to their potential for treating a broad…
The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions
CAR T-cell therapy has transformed cancer treatment, offering new hope for patients with aggressive B cell malignancies like acute lymphoblastic…
Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials
Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…
Allogeneic CAR-T Cell Therapies: A major step forward
In a groundbreaking clinical trial, three individuals suffering from severe autoimmune diseases have entered remission following a novel CAR T…
A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology
Are antibody-drug conjugates (ADCs), principally comprised of an antibody, a cytotoxic payload and a linker, the next therapeutic modality of…
Improving the quality of human health
Contact us
Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline
